Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto.
Data presented in a poster highlights the evaluation of a maximum tolerated dose of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks.
In a statement, Dr. Harald Hampel, a member of Anavex’s scientific advisory board, said the ANAVEX 2-73 data is prerequisite information in order to progress into Phase 2/3 placebo controlled studies.
ANAVEX 2-73 continues to demonstrate a favorable adverse event profile through 31 weeks in a patient population of elderly Alzheimer’s patients with varying degrees of physical fragility.
“We are encouraged by these new results, which provide us with valuable knowledge about ANAVEX 2-73 and allow us to proceed methodically in the development of ANAVEX 2-73,” said Christopher Missling, president and CEO.